Esperion Therapeutics, Inc. — Form 8-K
Filed July 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Essence Parent Inc. completed its acquisition of Esperion Therapeutics, Inc. on July 13, 2026. Esperion shareholders receive $3.16 cash per share plus contingent value rights (CVRs) tied to sales milestones: up to $40M if Bempedoic Acid Products achieve $300M+ annual US sales in 2027; up to $60M if Enbumyst achieves $160M+ annual US sales by end-2030. Convertible noteholders receive $1,032.68 cash and 326.80 CVRs per $1,000 principal, or $1,232.62 cash and 390.07 CVRs if converting in connection with the make-whole fundamental change.
Why this rating
Merger completed; $198M company acquired at modest cash consideration. CVR upside depends entirely on product sales achievement outside Esperion's control post-acquisition. Boilerplate governance/administrative filings.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.